Updated Story FDA’s approval Wednesday (Aug. 14) of a new drug for treatment-resistant forms of tuberculosis developed by the nonprofit TB Alliance refueled debate on the role the government and nonprofits could play in spurring the development of new antibiotics. While some experts call for greater investment in nonprofits such as TB Alliance, others say sustainable innovation requires new government reimbursement incentives to move reluctant pharmaceutical makers into the space due to the high costs and failure...